Literature DB >> 21159106

Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival.

Louise Barbier1, Olivier Turrini, Emilie Grégoire, Frédéric Viret, Yves-Patrice Le Treut, Jean-Robert Delpero.   

Abstract

BACKGROUND: This study assesses the impact of preoperative chemoradiation on recurrence, surgical morbidity, histopathological data and survival in resectable adenocarcinoma of the pancreatic head.
METHODS: We carried out a retrospective study with an intention-to-treat analysis. From 1997 to 2006, 173 patients with resectable pancreas head carcinoma were treated in two reference centres in France using different treatment strategies.
RESULTS: Sixty-seven of 85 (79%) patients in the surgery-first (SF) group and 38 of 88 (43%) patients in the chemoradiation (CR) group underwent surgical resection (P < 0.001). Overall morbidity was 40% (15/38) in the CR group and 43% (29/67) in the SF group (P= 0.837). In the CR group, median tumour size was smaller (1.5 cm vs. 3.0 cm; P < 0.001) and fewer patients were node-positive (29% vs. 64%; P= 0.001) than in the SF group. There was less perineural (43% vs. 93%; P < 0.001), lymphatic and vascular (21% vs. 92%; P < 0.001) invasion in the CR group than in the SF group. In both groups, 89% of patients had recurrence (31/35 in the CR group and 57/64 in the SF group; P= 1.000), predominantly involving metastasis and carcinomatosis in the CR group (30/31 vs. 35/57; P < 0.001) and locoregional recurrence in the SF group (24/57 vs. 3/31; P= 0.002). Median survival for all patients and for resected patients in the CR and SF groups was, respectively, 15 months vs. 17 months, and 21 months vs. 18 months (P= non-significant).
CONCLUSIONS: Preoperative chemoradiation allows for good local control of the disease but does not increase survival, mainly for reasons of metastatic spread. Other options should be developed to improve both local and distant control of the disease.
© 2010 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159106      PMCID: PMC3019544          DOI: 10.1111/j.1477-2574.2010.00245.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  16 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 2.  Current therapies and advances in the treatment of pancreatic cancer.

Authors:  Andrea Mancuso; Fabio Calabrò; Cora N Sternberg
Journal:  Crit Rev Oncol Hematol       Date:  2006-05-24       Impact factor: 6.312

3.  Most pancreatic cancer resections are R1 resections.

Authors:  Irene Esposito; Jörg Kleeff; Frank Bergmann; Caroline Reiser; Esther Herpel; Helmut Friess; Peter Schirmacher; Markus W Büchler
Journal:  Ann Surg Oncol       Date:  2008-03-20       Impact factor: 5.344

4.  Pancreaticojejunostomy and Other Problems Associated With the Surgical Management of Carcinoma Involving the Head of the Pancreas: Report of Five Additional Cases of Radical Pancreaticoduodenectomy.

Authors:  C G Child
Journal:  Ann Surg       Date:  1944-06       Impact factor: 12.969

5.  Preoperative locoregional re-evaluation by endoscopic ultrasound in pancreatic ductal adenocarcinoma after neoadjuvant chemoradiation.

Authors:  Nicolas Bettini; Vincent Moutardier; Olivier Turrini; Erwann Bories; Geneviève Monges; Marc Giovannini; Jean-Robert Delpero
Journal:  Gastroenterol Clin Biol       Date:  2005 Jun-Jul

6.  Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.

Authors:  H Golcher; T Brunner; G Grabenbauer; S Merkel; T Papadopoulos; W Hohenberger; T Meyer
Journal:  Eur J Surg Oncol       Date:  2008-01-10       Impact factor: 4.424

7.  Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.

Authors:  Romuald Le Scodan; Françoise Mornex; Christian Partensky; Catherine Mercier; Pierre-Jean Valette; Marc Ychou; Pascal Roy; Jean-Yves Scoazec
Journal:  Am J Clin Oncol       Date:  2008-12       Impact factor: 2.339

8.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.

Authors:  Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie Abdalla; Huamin Wang; Gregg A Staerkel; Jeffrey H Lee; William A Ross; Eric P Tamm; Priya R Bhosale; Sunil Krishnan; Prajnan Das; Linus Ho; Henry Xiong; James L Abbruzzese; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

9.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Authors:  Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

Review 10.  Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature.

Authors:  Giuseppe Garcea; Ashley R Dennison; Clare J Pattenden; Christopher P Neal; Christopher D Sutton; David P Berry
Journal:  JOP       Date:  2008-03-08
View more
  15 in total

1.  Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.

Authors:  Deyali Chatterjee; Asif Rashid; Hua Wang; Matthew H Katz; Robert A Wolff; Gauri R Varadhachary; Jeffrey E Lee; Peter W Pisters; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Hua Wang; Alina C Iuga; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; Christopher H Crane; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2012-03       Impact factor: 6.394

3.  Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens.

Authors:  Jean Robert Delpero; Philippe Bachellier; Nicolas Regenet; Yves Patrice Le Treut; François Paye; Nicolas Carrere; Alain Sauvanet; Aurélie Autret; Olivier Turrini; Geneviève Monges-Ranchin; Jean Marie Boher
Journal:  HPB (Oxford)       Date:  2013-03-07       Impact factor: 3.647

4.  Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base.

Authors:  Lauren E Colbert; William A Hall; Dana Nickleach; Jeffrey Switchenko; David A Kooby; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; John Kauh; Jerome C Landry
Journal:  Cancer       Date:  2014-01-03       Impact factor: 6.860

5.  Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells.

Authors:  Usama A Fahmy; Shaimaa M Badr-Eldin; Hibah M Aldawsari; Nabil A Alhakamy; Osama A A Ahmed; Mohamed F Radwan; Basma G Eid; Shaban R M Sayed; Gamal A El Sherbiny; Walaa Abualsunun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

6.  Impact of preoperative therapy on patterns of recurrence in pancreatic cancer.

Authors:  Pavlos Papavasiliou; John P Hoffman; Steven J Cohen; Joshua E Meyer; James C Watson; Yun Shin Chun
Journal:  HPB (Oxford)       Date:  2013-02-20       Impact factor: 3.647

7.  Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head.

Authors:  Quentin Denost; Christophe Laurent; Jean-Philippe Adam; Maylis Capdepont; Veronique Vendrely; Denis Collet; Antonio Sa Cunha
Journal:  HPB (Oxford)       Date:  2013-01-10       Impact factor: 3.647

8.  Clinical impact of additional therapy for residual pancreatic cancer.

Authors:  Suguru Yamada; Fuminori Sonohara; Mitsuru Tashiro; Kenta Murotani; Hideki Takami; Masamichi Hayashi; Mitsuro Kanda; Chie Tanaka; Daisuke Kobayashi; Goro Nakayama; Masahiko Koike; Tsutomu Fujii; Yasuhiro Kodera
Journal:  Surg Today       Date:  2019-10-24       Impact factor: 2.549

9.  Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy.

Authors:  Caitlin A McIntyre; Constantinos P Zambirinis; Alessandra Pulvirenti; Joanne F Chou; Mithat Gonen; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Murray F Brennan; Jeffrey A Drebin; William R Jarnagin; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2020-05-25       Impact factor: 5.344

Review 10.  Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Kyung Su Kim; Jeanny Kwon; Kyubo Kim; Eui Kyu Chie
Journal:  Cancer Res Treat       Date:  2016-08-26       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.